GBM exhibited increased expression levels of the MCT genes SLC16A1 and SLC16A3 when compared to normal brain parenchyma, as well as oligodendrogliomas and astrocytomas [39]. This evidence concerns the gene SLC16A1 and astrocytoma (excluding glioblastoma).